Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06029426
Other study ID # NMRA-335140-301
Secondary ID KOASTAL-1
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 20, 2023
Est. completion date July 2025

Study information

Verified date June 2024
Source Neumora Therapeutics, Inc.
Contact Study Contact
Email explore@koastalstudy.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA 335140 501).


Recruitment information / eligibility

Status Recruiting
Enrollment 332
Est. completion date July 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Key inclusion criteria: - Have a primary Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) diagnosis of MDD without psychotic features confirmed by Structured Clinical Interview for DSM 5 Disorders, Clinical Trials Version (SCID 5 CT) at screening (this may be a first or recurrent episode). - Participant's current major depressive episode must be confirmed by independent assessment. - The symptoms of the current MDD episode have been present for more than 4 weeks prior to the Screening Visit, but no longer than 12 months prior to the Screening Visit. - Have a MADRS total score of 25 or higher at Screening and Baseline. - A change in MADRS total score between Screening and Baseline of =20%. Key exclusion criteria: - Have failed 2 or more courses of antidepressant treatment at sufficient doses for at least 6 to 8 weeks for the current MDD episode. - Currently or in the past year have been diagnosed with a personality disorder per the DSM-5-TR or in the past 3 years have been diagnosed with any of the following DSM-5-TR disorders: anorexia nervosa, bulimia nervosa, or binge eating disorder. Participants with comorbid generalized anxiety disorder, social anxiety disorder, simple phobias, or panic disorder for whom MDD is considered the primary diagnosis are not excluded. - Have a lifetime diagnosis of bipolar 1 or 2, schizophrenia, schizoaffective, schizophreniform, obsessive compulsive disorder, or posttraumatic stress disorder (PTSD). - Have moderate to severe substance or alcohol use disorder, per DSM-5-TR criteria, within the 12 months prior to screening (excluding nicotine). - Are actively suicidal (e.g., any suicide attempts within the past 12 months) or are at serious suicidal risk as indicated by any current suicidal intent, including a plan, as assessed by the Columbia Suicide Severity Rating Scale (C SSRS) (score of "YES" on suicidal ideation Item 4 or 5 within 3 months prior to Visit 1 [screening]) and/or based on clinical evaluation by the Investigator; or are homicidal, in the opinion of the Investigator. Participants who are currently hospitalized for MDD symptoms or suicidality are not allowed into the study. If there is a recent history (within 3 months of screening) of hospitalization due to MDD symptoms, the participant should be discussed with the Medical Monitor for eligibility.

Study Design


Intervention

Drug:
NMRA 335140
Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Placebo
Placebo will be administered orally

Locations

Country Name City State
United States Neumora Investigator Site Allentown Pennsylvania
United States Neumora Investigator Site Austin Texas
United States Neumora Investigator Site Bellevue Washington
United States Neumora Investigator Site Bellflower California
United States Neumora Investigator Site Bentonville Arkansas
United States Neumora Investigator Site Bloomfield Hills Michigan
United States Neumora Investigator Site Boston Massachusetts
United States Neumora Investigator Site Brooklyn New York
United States Neumora Investigator Site Cedarhurst New York
United States Neumora Investigator Site Charlottesville Virginia
United States Neumora Investigator Site Chicago Illinois
United States Neumora Investigator Site Cleveland Ohio
United States Neumora Investigator Site Colorado Springs Colorado
United States Neumora Investigator Site Columbus Ohio
United States Neumora Investigator Site Dallas Texas
United States Neumora Investigator Site Dayton Ohio
United States Neumora Investigator Site Evanston Illinois
United States Neumora Investigator Site Everett Washington
United States Neumora Investigator Site Flowood Mississippi
United States Neumora Investigator Site Gainesville Florida
United States Neumora Investigator Site Garden Grove California
United States Neumora Investigator Site Garfield Heights Ohio
United States Neumora Investigator Site Glendale California
United States Neumora Investigator Site Hallandale Beach Florida
United States Neumora Investigator Site Houston Texas
United States Neumora Investigator Site Houston Texas
United States Neumora Investigator Site Huntsville Alabama
United States Neumora Investigator Site Imperial California
United States Neumora Investigator Site Jacksonville Florida
United States Neumora Investigator Site Lafayette California
United States Neumora Investigator Site Las Vegas Nevada
United States Neumora Investigator Site Lauderhill Florida
United States Neumora Investigator Site Little Rock Arkansas
United States Neumora Investigator Site Long Beach California
United States Neumora Investigator Site Los Angeles California
United States Neumora Investigator Site Maitland Florida
United States Neumora Investigator Site Marietta Georgia
United States Neumora Investigator Site Media Pennsylvania
United States Neumora Investigator Site Memphis Tennessee
United States Neumora Investigator Site Methuen Massachusetts
United States Neumora Investigator Site Miami Florida
United States Neumora Investigator Site Miami Florida
United States Neumora Investigator Site Miami Florida
United States Neumora Investigator Site Miami Lakes Florida
United States Neumora Investigator Site New York New York
United States Neumora Investigator Site Oceanside California
United States Neumora Investigator Site Orange California
United States Neumora Investigator Site Orlando Florida
United States Neumora Investigator Site Phoenix Arizona
United States Neumora Investigator Site Plymouth Meeting Pennsylvania
United States Neumora Investigator Site Riverside California
United States Neumora Investigator Site Rogers Arkansas
United States Neumora Investigator Site Saint Charles Missouri
United States Neumora Investigator Site San Jose California
United States Neumora Investigator Site Sherman Oaks California
United States Neumora Investigator Site #1 Sherman Oaks California
United States Neumora Investigator Site Staten Island New York
United States Neumora Investigator Site Tampa Florida
United States Neumora Investigator Site Temecula California
United States Neumora Investigator Site Torrance California
United States Neumora Investigator Site Warrenville Illinois
United States Neumora Investigator Site Watertown Massachusetts
United States Neumora Investigator Site Wichita Falls Texas

Sponsors (1)

Lead Sponsor Collaborator
Neumora Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. Thus, scores in the MADRS range from 0 to 60, with increasing scores indicating increasing severity. Baseline and up to Week 6
Secondary Change from Baseline to Week 6 assessed in the Snaith-Hamilton Pleasure Scale (SHAPS) total score The SHAPS is a 14 item participant-reported instrument which measures anhedonia. It has been shown to be valid and reliable in normal and clinical samples, with adequate construct validity, satisfactory test-retest reliability and high internal consistency. The scale will be completed by the participant and reviewed by site personnel qualified to oversee completeness. Each of the 14 items has a set of 4 responses, 2 of which endorse agreement (Definitely Agree, Agree) and 2 of which endorse disagreement (Disagree, Strongly Disagree). A total score can be derived by summing the response items, where those answered with "strongly agree" will be coded as a 1, while a "strongly disagree" response will be coded as 4. Therefore, scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia. Baseline and up to Week 6
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A